Browse USP22

Summary
SymbolUSP22
Nameubiquitin specific peptidase 22
Aliases KIAA1063; USP3L; ubiquitin specific protease 22; ubiquitin specific peptidase 3-like; deubiquitinating enzym ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00443 Ubiquitin carboxyl-terminal hydrolase
PF02148 Zn-finger in ubiquitin-hydrolases and other protein
Function

Histone deubiquitinating component of the transcription regulatory histone acetylation (HAT) complex SAGA. Catalyzes the deubiquitination of both histones H2A and H2B, thereby acting as a coactivator. Recruited to specific gene promoters by activators such as MYC, where it is required for transcription. Required for nuclear receptor-mediated transactivation and cell cycle progression.

> Gene Ontology
 
Biological Process GO:0006473 protein acetylation
GO:0006475 internal protein amino acid acetylation
GO:0007346 regulation of mitotic cell cycle
GO:0016570 histone modification
GO:0016573 histone acetylation
GO:0016574 histone ubiquitination
GO:0016578 histone deubiquitination
GO:0016579 protein deubiquitination
GO:0018205 peptidyl-lysine modification
GO:0018393 internal peptidyl-lysine acetylation
GO:0018394 peptidyl-lysine acetylation
GO:0043543 protein acylation
GO:0043967 histone H4 acetylation
GO:0045787 positive regulation of cell cycle
GO:0045931 positive regulation of mitotic cell cycle
GO:0070646 protein modification by small protein removal
Molecular Function GO:0003713 transcription coactivator activity
GO:0004402 histone acetyltransferase activity
GO:0004843 thiol-dependent ubiquitin-specific protease activity
GO:0008080 N-acetyltransferase activity
GO:0008234 cysteine-type peptidase activity
GO:0010485 H4 histone acetyltransferase activity
GO:0016407 acetyltransferase activity
GO:0016410 N-acyltransferase activity
GO:0016746 transferase activity, transferring acyl groups
GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups
GO:0019783 ubiquitin-like protein-specific protease activity
GO:0030374 ligand-dependent nuclear receptor transcription coactivator activity
GO:0034212 peptide N-acetyltransferase activity
GO:0036459 thiol-dependent ubiquitinyl hydrolase activity
GO:0061733 peptide-lysine-N-acetyltransferase activity
GO:0101005 ubiquitinyl hydrolase activity
Cellular Component GO:0000123 histone acetyltransferase complex
GO:0000124 SAGA complex
GO:0031248 protein acetyltransferase complex
GO:0070461 SAGA-type complex
GO:1902493 acetyltransferase complex
GO:1905368 peptidase complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-5688426: Deubiquitination
R-HSA-3214847: HATs acetylate histones
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-5689880: Ub-specific processing proteases
Summary
SymbolUSP22
Nameubiquitin specific peptidase 22
Aliases KIAA1063; USP3L; ubiquitin specific protease 22; ubiquitin specific peptidase 3-like; deubiquitinating enzym ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between USP22 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolUSP22
Nameubiquitin specific peptidase 22
Aliases KIAA1063; USP3L; ubiquitin specific protease 22; ubiquitin specific peptidase 3-like; deubiquitinating enzym ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of USP22 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 1.28; FDR: 0.031600 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolUSP22
Nameubiquitin specific peptidase 22
Aliases KIAA1063; USP3L; ubiquitin specific protease 22; ubiquitin specific peptidase 3-like; deubiquitinating enzym ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of USP22 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1350.505
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1120.964
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3120.871
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2650.383
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2560.917
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2820.931
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0830.862
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1070.961
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0960.969
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0260.989
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4360.871
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.030.637
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of USP22 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolUSP22
Nameubiquitin specific peptidase 22
Aliases KIAA1063; USP3L; ubiquitin specific protease 22; ubiquitin specific peptidase 3-like; deubiquitinating enzym ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of USP22. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolUSP22
Nameubiquitin specific peptidase 22
Aliases KIAA1063; USP3L; ubiquitin specific protease 22; ubiquitin specific peptidase 3-like; deubiquitinating enzym ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of USP22. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by USP22.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolUSP22
Nameubiquitin specific peptidase 22
Aliases KIAA1063; USP3L; ubiquitin specific protease 22; ubiquitin specific peptidase 3-like; deubiquitinating enzym ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of USP22. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolUSP22
Nameubiquitin specific peptidase 22
Aliases KIAA1063; USP3L; ubiquitin specific protease 22; ubiquitin specific peptidase 3-like; deubiquitinating enzym ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of USP22 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolUSP22
Nameubiquitin specific peptidase 22
Aliases KIAA1063; USP3L; ubiquitin specific protease 22; ubiquitin specific peptidase 3-like; deubiquitinating enzym ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between USP22 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolUSP22
Nameubiquitin specific peptidase 22
Aliases KIAA1063; USP3L; ubiquitin specific protease 22; ubiquitin specific peptidase 3-like; deubiquitinating enzym ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting USP22 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.